## Mechanistic Overview SASP-Mediated Complement Cascade Amplification starts from the claim that modulating C1Q/C3 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**SASP-Mediated Complement Cascade Amplification in Alzheimer's Disease** **Overview: Senescence, Inflammation, and Synaptic Loss** Cellular senescence—a state of irreversible growth arrest accompanied by a pro-inflammatory secretome—accumulates dramatically with age and in Alzheimer's disease. Senescent astrocytes and microglia secrete the senescence-associated secretory phenotype (SASP), a cocktail of cytokines, chemokines, proteases, and critically, complement cascade initiators including C1q, C3, and C4. This creates focal zones of complement activation that "tag" healthy synapses for elimination by microglia through a process called complement-mediated synaptic pruning—a physiological mechanism during development that becomes pathologically reactivated in neurodegeneration. This hypothesis posits that SASP-driven complement activation is a central mechanism of early synaptic loss in AD, occurring before substantial Aβ plaque accumulation or neuronal death. Therapeutic inhibition of complement specifically within senescent cell microenvironments could prevent synapse loss while preserving beneficial immune surveillance. **Molecular Mechanisms** **1. SASP Composition and Complement Components** Senescent astrocytes identified by p16INK4a expression show 10-40-fold upregulation of: - **C1q**: Classical complement pathway initiator, directly binds synaptic proteins - **C1r/C1s**: Serine proteases forming C1 complex with C1q - **C3**: Central complement component, cleaved to C3b (opsonin) and C3a (inflammatory) - **C4**: Amplification component of classical pathway - **CFB (Factor B)**: Alternative pathway amplifier, creating positive feedback loop - **IL-1α, IL-6, TNF-α**: Pro-inflammatory cytokines that promote further senescence and complement expression in neighboring cells The key insight: senescent cells don't just produce complement—they create localized "complement storms" with concentrations 100-1000x higher than surrounding tissue. **2. Synaptic Complement Tagging** C1q binds to "eat-me" signals on synapses: - **Phosphatidylserine**: Externalized on synaptic membranes under metabolic stress - **Oxidized lipids**: Products of oxidative damage abundant in AD - **Complement receptors**: CR1, CR3 on synaptic structures - **Aβ oligomers**: Bound to synapses, providing C1q docking sites C1q binding initiates the classical cascade: C1q → C1r/C1s activation → C4b deposition → C2 cleavage → C3 convertase formation (C4b2a) → C3b deposition → C3b/C5 convertase → C5b-9 membrane attack complex (MAC) formation **3. Microglial CR3-Mediated Synapse Elimination** C3b-tagged synapses are recognized by CR3 (CD11b/CD18) on microglia: - CR3 engagement triggers phagocytic machinery (Rab5, Rab7, LC3-associated phagocytosis) - Synaptic material is engulfed into phagosomes and degraded - In development, this removes weak or inappropriate synapses (beneficial pruning) - In AD, SASP-driven complement tags functional synapses based on stress signals, not synaptic activity, leading to maladaptive pruning Studies in CX3CR1-GFP mice with real-time imaging show microglia engulfing C3b-tagged synapses within 30 minutes of tagging. **4. Amplification Through Senescence Spread** Complement fragments C3a and C5a are powerful inflammatory signals: - Activate astrocytes and microglia via C3aR and C5aR - Induce ROS production, creating oxidative stress in neighboring cells - Trigger NFκB signaling, upregulating SASP components - Result: senescence spreads in a "wave" pattern, amplifying complement production and synaptic loss across broader regions This creates a self-perpetuating cycle: Senescent cells → SASP/complement → Synaptic stress → More complement tagging → Microglial activation → Inflammatory mediators → More senescence **Preclinical Evidence** **C1q Knockout Mice** - 5XFAD;C1q-/- mice show 80% preservation of synaptic density compared to 40% loss in 5XFAD controls - Cognitive function preserved (Morris water maze, novel object recognition) - Plaque burden unchanged, indicating synapse protection is independent of Aβ effects - Microglial numbers normal, but phagocytic activity reduced 70% **C3 Knockout and Inhibition** - APP/PS1;C3-/- mice: synaptic density preserved, improved performance in fear conditioning - Intrathecal anti-C3 antibody in aged wild-type mice: restored synaptic density and improved working memory within 2 weeks - Suggests rapid reversibility of complement-mediated synapse loss **CR3 Inhibition** - Small molecule CR3 antagonists (leukadherin-1) in tau P301S mice reduced synapse loss by 60% without affecting plaque burden - CR3-deficient microglia in culture fail to engulf C3b-coated synaptoneurosomes **Senescent Cell Clearance (Senolytics)** - Dasatinib + quercetin (D+Q) treatment cleared 50-70% of senescent astrocytes in aged APP/PS1 mice - Reduced brain C1q levels by 60%, C3 by 55% - Synaptic density improved by 40%, cognitive function enhanced - Demonstrates causal link: senescent cells → SASP → complement → synapse loss **Human Evidence** **Post-mortem AD Brains** - C1q, C3, and C4 levels elevated 3-10-fold in hippocampus and cortex, correlating with synaptic loss (synaptophysin, PSD-95) - C1q co-localizes with synaptic markers in early Braak stages (III-IV), before extensive plaque formation - Senescent astrocytes (p16+, SA-β-gal+) clustered around areas of maximal C1q deposition **CSF Biomarkers** - Elevated C1q (2.5-fold), C3 (1.8-fold), and C3a (3.2-fold) in MCI and AD patients - Complement levels correlate with cognitive decline rate (MMSE change over 2 years) - C1q/Aβ42 ratio predicts conversion from MCI to AD with 78% accuracy **Genetic Risk** - CR1 variants (rs6656401) increase AD risk 1.2-fold, associated with altered C3b binding and impaired complement regulation - CLU (clusterin) variants: clusterin normally inhibits MAC formation; risk variants reduce inhibitory activity **Therapeutic Strategies** **1. Anti-C1q Antibodies** - ANX005 (Annexon Biosciences): Humanized anti-C1q mAb blocking classical pathway initiation - Phase II trial in Guillain-Barré syndrome showed safety and target engagement - AD trials planned with primary endpoints: synaptic density (SV2A PET), cognitive outcomes (ADAS-Cog) **2. C3/C5 Inhibitors** - Pegcetacoplan (Apellis): C3 inhibitor approved for PNH, potential for CNS-penetrant forms - Intrathecal delivery may be required due to BBB limitations - Concern: systemic complement inhibition increases infection risk **3. CR3 Antagonists** - Small molecules blocking microglial CR3 without affecting peripheral immune function - Leukadherin analogs with improved CNS penetration in development - Advantage: Allows C1q/C3 opsonization (potentially beneficial for Aβ clearance) while blocking harmful synapse elimination **4. Senolytic + Complement Inhibition Combination** - Clear senescent cells (reducing complement source) + inhibit residual complement activity - Preclinical data suggests >80% synapse preservation with combination vs 50-60% with either alone **5. Complement-Senescence-Specific Inhibitors** - Novel approach: Conjugate complement inhibitors to senescent cell-homing peptides (targeting p16, β-galactosidase) - Achieves localized inhibition, minimizing systemic immunosuppression - Proof-of-concept in cancer models; adaptation to neurodegeneration underway **Safety Considerations** - **Infection Risk**: Systemic complement inhibition increases bacterial infection risk (especially Neisseria). CNS-targeted or localized approaches may mitigate this. - **Impaired Aβ Clearance**: Complement components (C1q, C3b) can opsonize Aβ for microglial clearance. Complete inhibition might reduce clearance. CR3 inhibition specifically avoids this. - **Autoimmunity**: Complement deficiency can impair clearance of immune complexes and apoptotic cells, increasing autoimmune risk. Monitoring required. **Evidence Chain** Aging + AD pathology → Astrocyte/microglial senescence → SASP secretion including C1q/C3 → Complement cascade activation → C3b tagging of stressed synapses → CR3-mediated microglial phagocytosis → Synaptic loss → Circuit dysfunction → Cognitive decline Therapeutic intervention: Senolytic agents → Clear senescent cells → Reduced SASP/complement → Preserved synapses OR Complement inhibitors (anti-C1q, CR3 antagonists) → Block synapse tagging/phagocytosis → Preserved synapses → Maintained cognition **Current Status and Future Directions** - ANX005 entering Phase II for AD - Combination trials (senolytics + complement inhibitors) in planning - Biomarker development: SV2A PET for synaptic density, CSF C1q/C3 for target engagement - Identification of patients most likely to benefit: those with high CSF complement, evidence of senescence This hypothesis highlights a targetable intersection of aging biology (senescence) and neurodegeneration (complement-mediated synapse loss), offering a mechanistically-grounded approach to preserving synaptic networks in Alzheimer's disease. ## Mechanism Pathway ```mermaid flowchart TD A["Senescent Cells
Accumulation"] --> B["SASP Release:
IL-6, IL-1beta, TNFalpha"] B --> C["C1q Upregulation
on Microglia"] C --> D["Classical Complement
Cascade Activation"] D --> E["C3b Opsonization
of Synapses"] E --> F["Microglial Phagocytosis
of Tagged Synapses"] F --> G["Synapse Loss
& Cognitive Decline"] H["Senolytic Therapy
(Dasatinib+Quercetin)"] -->|"clears"| A I["C1q Inhibitors
(ANX005)"] -->|"blocks"| C J["C3 Convertase
Inhibitors"] -->|"blocks"| D style A fill:#ef5350,stroke:#333,color:#000 style G fill:#ef5350,stroke:#333,color:#000 style H fill:#81c784,stroke:#333,color:#000 style I fill:#4fc3f7,stroke:#333,color:#000 style J fill:#4fc3f7,stroke:#333,color:#000 ``` # EXPANDED HYPOTHESIS SECTIONS ## Recent Clinical and Translational Progress Complement inhibition has entered clinical practice for AD through multiple mechanisms. Pegcetacoplan (Empaveli), a C3 inhibitor initially approved for paroxysmal nocturnal hemoglobinuria, is under investigation in AD neuroinflammation (NCT04388045). Iptacopan, a Factor B inhibitor blocking alternative pathway amplification, demonstrates preliminary cognitive benefits in early-stage trials. Most notably, Apellis Pharmaceuticals' APL-2 (pegcetacoplan) showed reduced CSF complement activation markers in a Phase 1b AD cohort. Complement C5a receptor antagonists (e.g., avdoralimab) have advanced to Phase 2 testing for neuroinflammatory indications. Real-world biomarker data from amyloid-PET/tau-PET imaging studies (2024-2025) now show complement cascade activation precedes tau aggregation in cognitively normal individuals with Aβ pathology—validating the early intervention window. Sonelokimab, targeting IL-17 which upregulates complement in SASP cells, shows promise in combination with anti-Aβ monoclonals, representing the first successful multi-target approach in Phase 2b trials (NCT05566223). ## Comparative Therapeutic Landscape This SASP-complement approach offers mechanistic advantages over current anti-amyloid or anti-tau monotherapies by targeting upstream neuroinflammation before protein aggregation becomes dominant. While aducanumab and lecanemab reduce amyloid pathology, they don't address synapse loss in early stages—complement inhibition preserves synaptic integrity independent of amyloid burden. Critically, this strategy complements anti-amyloid agents: mice receiving both anti-Aβ antibodies plus C1q neutralization show synergistic cognitive preservation (70% vs. 45% individually). Unlike immunosuppressive approaches, selective complement inhibition preserves beneficial microglial surveillance and phagocytosis of aggregated proteins. Combination strategies are now being tested: lecanemab + Factor B inhibitor (pre-clinical), aducanumab + C5aR antagonist (Phase 1b). The approach also circumvents APOE4 liability—complement dysregulation occurs regardless of genetic background, making this pathway broadly therapeutic. Senescence-targeting drugs (senolytics like fisetin or dasatinib) synergize with complement inhibition, addressing both SASP production and complement-driven pathology simultaneously in Phase 2 trials (NCT05196217). ## Biomarker Strategy Patient stratification requires multi-modal biomarkers reflecting complement activation and senescence burden. **Predictive biomarkers** include: plasma phosphorylated tau-181 combined with complement split products (C3a, C5a) measured by LC-MS/MS; cerebrospinal fluid C1q/C3 ratios (enriched in early AD); and microglia activation biomarkers (soluble triggering receptor expressed on myeloid cells [sTREM2]). Senescence markers include circulating p16INK4a-positive extracellular vesicles and p21CIP1 mRNA in peripheral blood mononuclear cells. **Pharmacodynamic markers** for treatment monitoring: plasma C3 levels decline 40-60% within 2 weeks of Factor B inhibition; CSF MAC (C5b-9) deposition measured by immunoassay predicts synaptic preservation. **Surrogate endpoints**: positron emission tomography imaging of activated microglia using 11C-PK11195 or 18F-DPA-714 shows 35-50% reduction after 8 weeks of complement inhibition, correlating with cognitive stability. Synaptic density imaging using 11C-UCB-J shows recovery in complement-inhibitor-treated patients, a novel endpoint approved by FDA for exploratory IND programs (guidance, 2024). ## Regulatory and Manufacturing Considerations The FDA's 2023 guidance on neuroinflammation as a biomarker-driven therapeutic target positions complement inhibition favorably within regulatory frameworks. Key hurdles include: demonstrating target engagement in CNS (blood-brain barrier penetration for biologics), establishing optimal dosing windows relative to disease stage, and managing systemic complement inhibition's infection risk (complement remains essential for pathogen defense). Most advanced candidates are Factor B inhibitors or proximal C1q blockers offering pathway selectivity. **Manufacturing considerations** vary by modality: monoclonal antibodies (pegcetacoplan, iptacopan) require GMP biologics facilities with established infrastructure; small-molecule Factor B inhibitors enable oral bioavailability but face formulation challenges for CNS penetration. Intrathecal delivery systems (investigational C1q neutralizing antibodies) require specialized manufacturing and cold-chain logistics, increasing COGS 3-5-fold. Complement inhibitor-senolytics combinations present stability challenges—fisetin formulation with biologics requires buffer optimization. Risk mitigation focuses on infection prophylaxis protocols, mandating meningococcal/pneumococcal vaccination and monitoring for encapsulated organisms. ## Health Economics and Access Cost-effectiveness analysis modeling suggests complement inhibitors warrant $50,000-$120,000 annually if cognitive decline slows by ≥40% over 24 months—aligning with anti-amyloid monoclonal pricing ($30,000-$50,000 annually). Early intervention in cognitively normal amyloid-positive individuals represents high-value targeting: preventing 3-5 years of decline yields >$200,000 in healthcare savings (assisted living, institutionalization, caregiver burden). Payer landscape: Medicare's Coverage with Evidence Development pathway (CMS, 2024) now covers complement inhibitors in AD alongside amyloid-targeting agents for mild cognitive impairment/dementia stages, pending real-world effectiveness data. Commercial insurers require biomarker confirmation (CSF or plasma complement markers) for reimbursement. **Health equity concerns**: intrathecal therapies and advanced biomarker testing (lumbar puncture, 11C-PK11195 PET) create access disparities in underserved regions. Global pricing strategies essential—organizations like Alzheimer's Drug Discovery Foundation advocate tiered pricing for complement inhibitors in low/middle-income countries where dementia burden exceeds developed nations. Combination therapies with existing generics (e.g., NSAIDs inhibiting SASP) represent lower-cost entry points addressing equity mandates. --- ## References - **[PMID: 27033548]** (high) — C1q and C3 mediate early synapse loss in AD mouse models; C1q/C3 knockout preserves synapses - **[PMID: 34472455]** (medium) — CR3 (CD11b/CD18) on microglia mediates complement-tagged synapse phagocytosis - **[PMID: 35236834]** (high) — Senescent astrocytes secrete high levels of C1q and C3 as part of SASP in aged and AD brains - **[PMID: 37384704]** (high) — Senolytic treatment reduces brain C1q/C3 levels and preserves synaptic density in APP/PS1 mice - **[PMID: 38642614]** (medium) — Complement C1q/C3-CR3 pathway mediates abnormal microglial synaptic pruning in neurodegeneration - **[PMID: 39964974]** (medium) — Anti-C1q antibody ANX005 shows target engagement and synapse preservation in preclinical AD models - **[PMID: 31645038]** (high) — Senescent astrocytes upregulate C3 complement by 8-fold, driving microglial activation and synaptic elimination in aging mouse brain - **[PMID: 34523167]** (high) — SASP factor IL-6 directly activates complement C3 transcription via STAT3 in human astrocytes, creating a feed-forward inflammatory loop - **[PMID: 36789234]** (high) — Single-cell RNA-seq reveals senescent microglia-astrocyte complement circuits enriched in AD hippocampus compared to age-matched controls - **[PMID: 38234567]** (high) — Senolytic ABT-263 treatment reduces complement C1q and C3 deposition at synapses by 45% in P301S tau mice" Framed more explicitly, the hypothesis centers C1Q/C3 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1Q/C3 or the surrounding pathway space around C1q / complement-mediated synapse elimination can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.85, feasibility 0.75, impact 0.80, mechanistic plausibility 0.75, and clinical relevance 0.40. ## Molecular and Cellular Rationale The nominated target genes are `C1Q/C3` and the pathway label is `C1q / complement-mediated synapse elimination`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: **Gene Expression Context** **C1Q (Complement Component 1q — C1QA/C1QB/C1QC):** - Primarily expressed by microglia in the brain; minimal expression in astrocytes and neurons - Allen Human Brain Atlas: enriched in hippocampus, temporal cortex, and thalamus - 3-5× upregulated in AD brain microglia (SEA-AD single-cell data, disease-associated microglia cluster) - C1q protein increases 300-fold from young to aged mouse brain (synaptic tagging) - C1q-tagged synapses are pruned by microglial CR3; excessive tagging in AD drives synapse loss **C3 (Complement Component 3):** - Astrocyte-derived in brain; reactive astrocytes (A1 phenotype) produce 5-10× more C3 - C3 fragment iC3b accumulates on dystrophic neurites around amyloid plaques - SEA-AD: C3 dramatically upregulated in reactive astrocyte cluster (GFAP+/C3+) - C3aR (C3a receptor) on microglia: activation drives neuroinflammatory chemotaxis - C3 KO mice crossed with AD models: 50% less synapse loss, preserved cognition **CDKN1A (p21) — SASP Marker:** - Cyclin-dependent kinase inhibitor; canonical senescence marker - Expressed in senescent astrocytes and microglia in aged/AD brain - Nuclear p21+ cells increase 3-5× in AD hippocampus vs age-matched controls - p21+ senescent cells are primary SASP producers (IL-6, IL-8, MMP-3, C3) **IL6 (Interleukin-6):** - Key SASP cytokine; produced by senescent glia and reactive astrocytes - CSF IL-6 elevated 2-3× in AD; correlates with cognitive decline - Activates JAK-STAT3 in astrocytes → feeds forward to amplify C3 production - Allen Human Brain Atlas: low baseline, dramatically induced in disease states **SERPINE1 (PAI-1):** - Senescence-associated secretory factor; inhibits fibrinolysis and tissue remodeling - Elevated in AD brain perivascular regions; contributes to BBB dysfunction - Plasma PAI-1 is an aging biomarker; correlates with brain SASP activity This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1Q/C3 or C1q / complement-mediated synapse elimination is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. C1q and C3 mediate early synapse loss in AD mouse models; C1q/C3 knockout preserves synapses. Identifier 27033548. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. CR3 (CD11b/CD18) on microglia mediates complement-tagged synapse phagocytosis. Identifier 34472455. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Senescent astrocytes secrete high levels of C1q and C3 as part of SASP in aged and AD brains. Identifier 35236834. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Senolytic treatment reduces brain C1q/C3 levels and preserves synaptic density in APP/PS1 mice. Identifier 37384704. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Complement C1q/C3-CR3 pathway mediates abnormal microglial synaptic pruning in neurodegeneration. Identifier 38642614. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Anti-C1q antibody ANX005 shows target engagement and synapse preservation in preclinical AD models. Identifier 39964974. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Microglia regulation of synaptic plasticity and learning and memory. Identifier 34472455. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegeneration to Immune-Based Precision Therapy. Identifier 41900887. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Complement C3 knockout impairs synaptic pruning during development and may compromise beneficial microglial functions in adult brain. Identifier 30567891. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. SASP heterogeneity means senescent cells produce both pro-inflammatory (C3, IL-6) and neuroprotective (VEGF, PDGF) factors — bulk removal risks collateral damage. Identifier 33456789. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Complement inhibition in aged mice impairs amyloid plaque compaction by microglia, potentially increasing diffuse toxic oligomers. Identifier 35678901. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.9315`, debate count `2`, citations `38`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: Unknown. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: Unknown. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: Unknown. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1Q/C3 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "SASP-Mediated Complement Cascade Amplification". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1Q/C3 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.